- Home
- XERS vs ORIC Comparison
XERS vs ORIC Comparison
Compare XERS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- ORIC
- Stock Information
- Founded
- XERS 2005
- ORIC 2014
- Country
- XERS United States
- ORIC United States
- Employees
- XERS N/A
- ORIC N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- ORIC Health Care
- Exchange
- XERS Nasdaq
- ORIC Nasdaq
- Market Cap
- XERS 526.3M
- ORIC 545.5M
- IPO Year
- XERS 2018
- ORIC 2020
- Fundamental
- Price
- XERS $4.24
- ORIC $8.00
- Analyst Decision
- XERS Strong Buy
- ORIC Strong Buy
- Analyst Count
- XERS 4
- ORIC 10
- Target Price
- XERS $5.75
- ORIC $19.25
- AVG Volume (30 Days)
- XERS 2.4M
- ORIC 1.5M
- Earning Date
- XERS 03-06-2025
- ORIC 05-05-2025
- Dividend Yield
- XERS N/A
- ORIC N/A
- EPS Growth
- XERS N/A
- ORIC N/A
- EPS
- XERS N/A
- ORIC N/A
- Revenue
- XERS $203,070,000.00
- ORIC N/A
- Revenue This Year
- XERS $20.47
- ORIC N/A
- Revenue Next Year
- XERS $19.35
- ORIC N/A
- P/E Ratio
- XERS N/A
- ORIC N/A
- Revenue Growth
- XERS 23.89
- ORIC N/A
- 52 Week Low
- XERS $1.69
- ORIC $6.33
- 52 Week High
- XERS $4.50
- ORIC $16.37
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- ORIC 43.30
- Support Level
- XERS $3.59
- ORIC $7.30
- Resistance Level
- XERS $4.50
- ORIC $8.11
- Average True Range (ATR)
- XERS 0.25
- ORIC 0.69
- MACD
- XERS 0.03
- ORIC -0.01
- Stochastic Oscillator
- XERS 72.34
- ORIC 31.39
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.